JPMorgan Starts Enanta Pharmaceuticals (ENTA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Starts Enanta Pharmaceuticals (ENTA) at Outperform
April 15, 2013 8:20 AM EDTLeerink Swann, along with several other brokers, initiated coverage on recent IPO Enanta Pharmaceuticals (NASDAQ: ENTA) with a Outperform rating and $28 price target.
The firm comments, "ENTA offers an opportunity to participate in the multi-billion HCV market for IFN-free regimen as a... More
Credit Suisse Starts Enanta Pharmaceuticals (ENTA) at Outperform
April 15, 2013 8:07 AM EDTCredit Suisse initiates coverage on Enanta Pharmaceuticals (NASDAQ: ENTA) with a Outperform. PT $29.00.
For an analyst ratings summary and ratings history on Enanta Pharmaceuticals click here. For more ratings news on Enanta Pharmaceuticals click here.
Shares of Enanta Pharmaceuticals closed at $19.68 yesterday, with a 52 week range of $14.31-$22.17.... More
